Rayonier Advanced Materials Inc. (RYAM) stock
Close on Nov 13, 2026Market cap $382.19MP/E –Yield –
Earnings
Rayonier Advanced Materials's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Rayonier Advanced Materials's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 2, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 26, 2026 | Nov 3, 2026after the close | $383.00M | +8.5% | -$3.40 | – | Release |
| Q2 FY2026ended Jun 27, 2026 | Aug 4, 2026after the close | $376.00M | +10.6% | -$0.49 | – | Release |
| Q1 FY2026ended Mar 28, 2026 | May 5, 2026after the close | $319.00M | -10.4% | -$1.22 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 3, 2026after the close | $417.00M | -1.2% | -$0.32 | – | Release |
| Q3 FY2025ended Sep 27, 2025 | Nov 4, 2025after the close | $353.00M | -12.0% | -$0.07 | – | Release |
| Q2 FY2025ended Jun 28, 2025 | Aug 5, 2025after the close | $340.00M | -18.9% | -$5.44 | – | Release |
| Q1 FY2025ended Mar 29, 2025 | May 6, 2025after the close | $356.00M | -8.2% | -$0.49 | -$0.49 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 5, 2025after the close | $422.00M | 0.0% | -$0.25 | -$0.10 | Release |
| Q3 FY2024ended Sep 28, 2024 | Nov 5, 2024after the close | $401.00M | +8.7% | -$0.49 | -$0.12 | Release |
| Q2 FY2024ended Jun 29, 2024 | Aug 6, 2024after the close | $419.00M | +8.8% | $0.17 | $0.19 | Release |
| Q1 FY2024ended Mar 30, 2024 | May 7, 2024after the close | $388.00M | -16.9% | -$0.02 | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $422.00M | -15.6% | -$0.94 | -$0.22 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $369.00M | -20.8% | -$0.39 | -$0.40 | Release |
| Q2 FY2023ended Jul 1, 2023 | Aug 8, 2023after the close | $385.00M | -3.5% | -$0.26 | -$0.25 | Release |
| Q1 FY2023ended Apr 1, 2023 | May 9, 2023after the close | $467.00M | +32.7% | $0.02 | $0.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $500.00M | +33.7% | $0.05 | $0.04 | Release |
| Q3 FY2022ended Sep 24, 2022 | Nov 1, 2022after the close | $466.00M | +24.6% | $0.45 | $0.28 | Release |
| Q2 FY2022ended Jun 25, 2022 | Aug 3, 2022after the close | $399.00M | – | -$0.36 | -$0.31 | Release |
| Q1 FY2022ended Mar 26, 2022 | May 3, 2022after the close | $352.00M | – | -$0.39 | -$0.38 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022after the close | $374.00M | – | -$0.38 | -$0.37 | Release |
| Q3 FY2021ended Sep 25, 2021 | Nov 2, 2021after the close | $374.00M | – | -$0.07 | -$0.21 | Release |
| Q2 FY2021ended Jun 26, 2021 | Aug 3, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 27, 2021 | May 4, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 26, 2020 | Nov 4, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Rayonier Advanced Materials's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| run-rate EBITDAnon-GAAP | FY2027 | $300.00M | – | New | Nov 4, 2025 |
| run-rate EBITDAnon-GAAP | FY2027 | $300.00M | $42.00M | Raised | Aug 5, 2025 |
Guidance history
Every forecast Rayonier Advanced Materials put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2025 | Adjusted EBITDA | FY2025 | $135.00M – $140.00M | New |
| Nov 4, 2025 | Cellulose Specialties EBITDA | FY2025 | $227.00M – $230.00M | Raised |
| Nov 4, 2025 | Biomaterials EBITDA | FY2025 | $7.00M | Lowered |
| Nov 4, 2025 | Cellulose Commodities EBITDA | FY2025 | -$15.00M – -$13.00M | Lowered |
| Nov 4, 2025 | Paperboard EBITDA | FY2025 | $13.00M | Raised |
| Nov 4, 2025 | High-Yield Pulp EBITDA | FY2025 | -$27.00M | Lowered |
| Nov 4, 2025 | run-rate EBITDA | FY2027 | $300.00M | New |
| Nov 4, 2025 | Adjusted Free Cash Flow | Q4 FY2025 | $25.00M – $30.00M | New |
| Nov 4, 2025 | Corporate costs | FY2025 | $70.00M | New |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $150.00M – $160.00M | Raised |
| Aug 5, 2025 | EBITDA (Cellulose Specialties) | FY2025 | $232.00M – $235.00M | Raised |
| Aug 5, 2025 | EBITDA (Biomaterials) | FY2025 | $8.00M – $10.00M | Lowered |
| Aug 5, 2025 | EBITDA (Cellulose Commodities) | FY2025 | -$15.00M | Lowered |
| Aug 5, 2025 | EBITDA (Paperboard) | FY2025 | $20.00M | Raised |
| Aug 5, 2025 | EBITDA (High-Yield Pulp) | FY2025 | -$25.00M – -$20.00M | Lowered |
| Aug 5, 2025 | run-rate EBITDA | FY2027 | $300.00M | Raised |
| Aug 5, 2025 | Adjusted Free Cash Flow | FY2025 | -$25.00M – -$10.00M | Lowered |
| Aug 5, 2025 | Corporate costs | FY2025 | $70.00M | Lowered |
| May 6, 2025 | Capital expenditures, net | FY2025 | -$85.00M | New |
| May 6, 2025 | Adjusted EBITDA | FY2025 | $175.00M – $185.00M | Lowered |
| May 6, 2025 | EBITDA | FY2025 | $237.00M – $245.00M | Raised |
| May 6, 2025 | EBITDA | FY2025 | -$5.00M | Lowered |
| May 6, 2025 | EBITDA | FY2025 | $8.00M – $10.00M | Raised |
| May 6, 2025 | EBITDA | FY2025 | $25.00M | Raised |
| May 6, 2025 | EBITDA | FY2025 | -$20.00M | Lowered |
| May 6, 2025 | Adjusted Free Cash Flow | FY2025 | $5.00M – $15.00M | Lowered |
| May 6, 2025 | Corporate costs | FY2025 | $70.00M | New |
| May 6, 2025 | Depreciation and amortization | FY2025 | $125.00M | Raised |
| May 6, 2025 | Interest expense, net | FY2025 | $93.00M | Lowered |
| May 6, 2025 | Income tax benefit (b) | FY2025 | -$9.00M | Lowered |
| May 6, 2025 | Cash provided by operating activities | FY2025 | $90.00M – $100.00M | Raised |
| May 6, 2025 | Loss from continuing operations attributable to RYAM | FY2025 | -$34.00M – -$24.00M | New |
| Mar 5, 2025 | Adjusted EBITDA | FY2025 | $215.00M – $235.00M | New |
| Mar 5, 2025 | Adjusted Free Cash Flow | FY2025 | $25.00M – $45.00M | New |
| Nov 5, 2024 | Capital expenditures, net | FY2024 | -$78.00M | New |
| Nov 5, 2024 | EBITDA-continuing operations | FY2024 | $164.00M – $173.00M | Lowered |
| Nov 5, 2024 | Adjusted EBITDA | FY2024 | $205.00M – $215.00M | Reaffirmed |
| Nov 5, 2024 | annual EBITDA from all of RYAM’s future biomaterial products | FY2027 | $42.00M | New |
| Nov 5, 2024 | Adjusted Free Cash Flow | FY2024 | $115.00M – $125.00M | Raised |
| Nov 5, 2024 | Interest expense, net | FY2024 | $80.00M | Lowered |
| Nov 5, 2024 | Depreciation and amortization | FY2024 | $140.00M | New |
| Nov 5, 2024 | Income tax benefit | FY2024 | -$13.00M | Lowered |
| Nov 5, 2024 | Cash provided by operating activities | FY2024 | $193.00M – $203.00M | Raised |
| Nov 5, 2024 | Loss from continuing operations | FY2024 | -$43.00M – -$34.00M | New |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | $205.00M – $215.00M | Raised |
| Aug 6, 2024 | Adjusted Free Cash Flow | FY2024 | $100.00M – $110.00M | Raised |
| May 7, 2024 | Adjusted EBITDA | FY2024 | $180.00M – $200.00M | Reaffirmed |
| May 7, 2024 | Adjusted Free Cash Flow | FY2024 | $80.00M – $100.00M | Raised |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | $180.00M – $200.00M | New |
| Feb 27, 2024 | Adjusted Free Cash Flow | FY2024 | $20.00M – $40.00M | New |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $150.00M | Lowered |
| Nov 7, 2023 | Adjusted Free Cash Flow | FY2023 | $65.00M – $75.00M | Raised |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | $185.00M – $200.00M | Lowered |
| Aug 8, 2023 | Adjusted Free Cash Flow | FY2023 | $55.00M – $70.00M | Raised |
| May 9, 2023 | custodial capital expenditures | FY2023 | $100.00M – $105.00M | New |
| May 9, 2023 | Adjusted EBITDA | Q2 FY2023 | $40.00M | New |
| May 9, 2023 | Adjusted EBITDA | FY2023 | $200.00M – $215.00M | Reaffirmed |
| May 9, 2023 | Adjusted Free Cash Flow | FY2023 | $40.00M – $65.00M | Raised |
| May 9, 2023 | income (loss) from continuing operations | FY2023 | -$8.00M – $12.00M | Reaffirmed |
| Feb 27, 2023 | Adjusted EBITDA | FY2023 | $200.00M – $215.00M | New |
| Feb 27, 2023 | Adjusted Free Cash Flow | FY2023 | $30.00M – $60.00M | New |
| Feb 27, 2023 | income (loss) from continuing operations | FY2023 | -$8.00M – $12.00M | New |
| Nov 1, 2022 | Adjusted EBITDA | FY2022 | $175.00M | Raised |
| Aug 3, 2022 | Adjusted EBITDA | FY2022 | $160.00M | New |
| Aug 3, 2022 | Net Debt | FY2022 | $725.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Rayonier Advanced Materials filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Update
- News
See a number that looks wrong?